ArticleRSC advances2026
A Natural product-based composite nanozyme synergistically induces ferroptosis for lung cancer therapy.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of lung cancer remains a significant clinical challenge. Inducing ferroptosis is a promising therapeutic strategy to overcome treatment resistance in lung cancer. Herein, we report a composite nanozyme, Fe@Arc, engineered by coordinating arctigenin with iron ions followed by a high-temperature carbonization. This fabrication method yielded a nanozyme with a high drug-loading capacity and controlled release kinetics. Following intravenous administration, Fe@Arc efficiently accumulated at the tumor site owing to its enhanced permeability and retention effect. In the tumor site, it exerted a potent anti-tumor effect by catalyzing the Fenton reaction and releasing arctigenin, which synergistically triggered ferroptosis in cancer cells. This work presents a multifaceted platform that not only overcomes the pharmacological limitations of herbal extracts but also establishes a robust framework for developing novel ferroptosis inducers, demonstrating significant potential for clinical translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.